Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q _____________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of Regis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37359 | --- | --- | --- | |----------------------------------------------------------------------------------------- ...

Blueprint Medicines (NASDAQ:BPMC) Q4 2018 Earnings Conference Call February 26, 2019 8:30 AM ET Company Participants Jim Baker - Vice President, Corporate Affairs Jeff Albers - Chief Executive Officer Kate Haviland - Chief Operating Officer Andy Boral - Chief Medical Officer Mike Landsittel - Chief Finance Officer Conference Call Participants Jason Jakoby - Goldman Sachs Marc Frahm - Cowen and Company Arlinda Lee - Canaccord Charles Zhu - Guggenheim Partners Operator Good day, ladies and gentlemen, and welc ...